Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?

Table 6 Changes of night arterial stiffness parameters after 3 mo omega-3 polyunsaturated fatty acid therapy

	Patients with T2DM and CAN (n = 39)
	Groups	Baseline	After treatment	% change from baseline
AIxao (%)	Control group	33.2 ± 1.98	30.1 ± 1.27	-6.6% ± 4.15%
	Treatment group	36.6 ± 1.65	31.7 ± 1.23a	-11.2% ± 4.2%
AIxbr (%)	Control group	-4.2 ± 2.8	-5.9 ± 2.48	-10.0% ± 17.23%
	Treatment group	-1.6 ± 2.79	-10.4 ± 3.23a	-98.0% ± 18.1%
PWV (m/s)	Control group	10.9 ± 0.4	10.3 ± 0.36	-4.93% ± 1.41%
	Treatment group	11.3 ± 0.48	9.0 ± 0.44b	-18.9% ± 3.9%

The results are given as absolute values and as % change from baseline, (Δ%, Mean ± SEM);

^aP < 0.05,

^bP < 0.01, - compared to baseline. T2DM: Type 2 diabetes mellitus; CAN: Cardiac autonomic neuropathy; AIxao: Aortha augmentation index; AIxbr: Brachial augmentation index; PWV: Pulse wave velocity.